July 2024 in “Journal of Investigative Dermatology” IL-27 may help prevent hair loss in alopecia areata by promoting immunosuppressive T cells.
14 citations
,
February 2020 in “Scientific reports” Telocytes in the scalp may help with skin regeneration and maintenance.
32 citations
,
January 2017 in “Orphanet journal of rare diseases” FOXN1 gene mutations cause a rare, severe immune disease treatable with cell or tissue transplants.
November 2025 in “The Journal of Immunology” Different γδ T cell types have unique roles in causing alopecia areata.
September 2023 in “Journal of the American Academy of Dermatology” Increased Treg cells and IL-10 may help quick recovery in acute diffuse and total alopecia.
July 2026 in “The Journal of Immunology” Tacrolimus effectively promotes hair regrowth in an alopecia areata mouse model.
15 citations
,
April 2017 in “Cell Stem Cell” Some brain cancer cells avoid immune system detection, and certain treatments could target this to slow their growth; also, certain fat cell precursors help regenerate hair and skin after injury.
April 2023 in “Journal of Investigative Dermatology” Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
January 2024 in “Inflammation and regeneration” Th22 cells are essential for Tβ15-induced hair growth in mice.
3 citations
,
May 2019 in “Cytotherapy” ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.
4 citations
,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
July 2022 in “Journal of Investigative Dermatology” 28 citations
,
May 2012 in “Experimental Dermatology” Alopecia areata helps study T cell-driven autoimmune diseases.
288 citations
,
January 2001 in “Journal of Biological Chemistry” Tgm2 helps stabilize dying cells and aids fibroblast attachment to the extracellular matrix.
June 2026 in “Current Oncology Reports” Sacituzumab Tirumotecan shows promise in treating gynecologic cancers with manageable side effects.
21 citations
,
January 2024 in “Science Immunology” Regulatory T cells protect hair follicle stem cells by maintaining immune privilege in the skin.
July 2026 in “Journal of Ovarian Research” The study identified diverse cell types and gene expressions in ovarian steroid cell tumors, improving understanding of this rare tumor.
9 citations
,
October 2008 in “British Journal of Dermatology” The growth of the Epstein-Barr virus in the patient's cells was linked to the worsening of her lymphoma.
November 2024 in “Journal of Investigative Dermatology”
2 citations
,
July 2009 in “Circulation Research” CD133+ progenitor cells have therapeutic potential for diabetic ulcers and heart attack recovery, with manageable risks.
2 citations
,
November 1996 in “Transplantation” Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.
CD4 T cells need IFN-γ to cause hair loss in alopecia areata.
1 citations
,
May 2026 in “Nature Communications” CD19-CAR T cell therapy may help regenerate skin in systemic sclerosis.
14 citations
,
April 2015 in “Stem Cell Research & Therapy” Granulation tissue-derived cells can aid wound healing and serve as an alternative source of stem cells for tissue repair.
26 citations
,
February 2021 in “FEBS Journal” Targeting regulatory T cells may help treat age-related diseases.
32 citations
,
May 2023 in “Frontiers in Immunology” Understanding cellular interactions in VCA may lead to better treatments and reduce rejection.
30 citations
,
February 2023 in “Journal of Investigative Dermatology” OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.
62 citations
,
June 2015 in “The Journal of Dermatology” People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.
October 2025 in “Science Advances” IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
27 citations
,
September 1992 in “The Lancet” ICL is a condition with low CD4+ T cells like AIDS but not caused by HIV, and normal CD4+ T cell counts may vary between men and women.